Arch Pharmalabs, Ltd., a leading provider of small molecule process R&D and full life-cycle custom synthesis and manufacturing services, announced today it has entered into a strategic partnership with Orochem Technologies, Inc., to manufacture a U.S. innovator’s active pharmaceutical ingredient (API) in late-stage clinical development using Simulated Moving Bed (SMB) technology. Orochem Technologies manufactures SMB equipment and stationary chromatography phases for Bioanalytical, Solid Phase Extraction, Flash and Preparative applications. Financial terms were not disclosed.
The collaboration between Orochem Technologies and Arch Pharmalabs marks the first time that plant-scale SMB has been used to manufacture an API in India.
“We are proud to synergize our world-class API development and manufacturing capabilities with SMB technology to work on a U.S. innovator’s molecule in India,” said Ajit Kamath, CMD, Arch Pharmalabs. “Using our flexible SMB capabilities, we can rapidly and cost-effectively tackle separation and purification challenges during scale-up, and provide a reliable API or drug intermediate supply chain throughout the product lifecycle. Our collaboration with Orochem Technologies further strengthens our position as an innovation-driven company and a trusted development and manufacturing partner for global pharmaceutical companies.”
“By partnering with Arch Pharmalabs, we are better able to bring Orochem’s novel products and expertise to help pharmaceutical companies achieve higher efficiencies in manufacturing processes requiring separation or purification,” said Asha Oroskar, president and CEO, Orochem Technologies. “This collaboration will significantly benefit our customers by offering dependable and cost-effective solutions during API production.”
Small brain-penetrating molecule offers hope for treating aggressive brain tumors